Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05327010CT.gov Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | — | Recruiting | — | — | — |
NCT04991480CT.gov A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04550494CT.gov Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | — | Recruiting | — | — | — |
NCT04693468CT.gov Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | — | Recruiting | — | — | — |
NCT02317874CT.gov Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | — | Completed | — | — | — |
NCT02286687CT.gov Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes | — | Active Not Recruiting | — | — | — |
NCT02049593CT.gov PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Talazoparib (this asset) | National Cancer Institute (NCI) | P2 | CCC · 55 |
| Fluorouracilum | I-Mab Biopharma US Limited | P3 | BB |
| Irinotecan | Incyte Corporation | P3 | BB |
| Nivestim | Mayo Clinic | P3 | BB |
| Cyclophosphamide | InSilico Medicine Hong Kong Limited | P2/3 | BB |
| Pembrolizumab | InSilico Medicine Hong Kong Limited | P2/3 | BB |
| Letrozole | UNICANCER | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | National Cancer Institute (NCI) | P2/3 | BB |
| Anastrozole | UNICANCER | P3 | BB |
+42 more in the Metastatic Malignant Neoplasm cohort
Other indications for Talazoparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| BRCA2-Related Cancer Predisposition | — | P3 | BB · 68 |
| Castration-Resistant Prostate Carcinoma | — | P2 | BB · 65 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Talazoparib in Metastatic Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/talazoparib-metastatic-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →